Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics aimed at silencing genes that cause or contribute to disease, focusing on various difficult-to-treat diseases, including rare and common conditions.

Alnylam Pharmaceuticals

Domain Not Resolving

DNSSEC

reCAPTCHA

Cloudflare JS

CDN JS

Apple Mobile Web App Capable

ASP.NET

IIS 10

HSTS IncludeSubdomains PreLoad

President

Akshay Vaishnaw

Chief Technical Operations and Quality Officer

Al Boyle

Sr. Manager, Product Quality Owner, QA,

Anuja Patel

Global Head of Clinical Supply Chain and CMO Management

Charlie Hitscherich

VP, Chief Accounting Officer

Cindy Anderson

Sr. Specialist, CMO Management

Danielle Dougherty

SVP, Chief Information Officer (CIO)

James Bilotta

Chief Financial Officer

Jeff Poulton

Chief Executive Officer & Director

John Maraganore

Chief Human Resources Officer

Kelley Boucher

Robert Nelsen

Daniel J. Rader

Dennis Ausiello

Phillip Sharp

John Clarke

Steven Paul

Paul Schimmel

Lubomir Nechev

Vice President Process and Analytical Sciences

Roumen Radinov

Director, Process Chemistry

Eric Raichle

Vice President, Human Resources

Muthiah Manoharan

Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist

Mary Beth DeLena

VP, Legal

Steve Bossone

Senior Vice President, Chief Patent Counsel

Greater Boston Area Companies (Top 10K)

Therapeutics Companies that Exited

East Coast Public Companies With More Than $1B in Revenue

Health Care Companies With More Than 10 Employees (Top 10K)

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Post-IPO Debt - Alnylam Pharmaceuticals

Blackstone Life Sciences

Post-IPO Equity - Alnylam Pharmaceuticals

Blackstone Credit

Regeneron

Genzyme

Takeda

Private Equity Round - Alnylam Pharmaceuticals

Cambridge

Massachusetts

United States

North America

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

North America RNA Therapeutics Market Research 2024-2029: Revolutionary Advancements in RNA Technology and Personalized Medicine Propel Growth

Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)

Alnylam downgraded at Wolfe on doubts over Amvuttra growth

‘Very nervous’: After Trump victory, concerns about Affordable Care Act’s future weigh on some in health care sector

Key Factors Influencing the 2024 Oligonucleotide Therapy Market: The Rising Cancer Epidemic

Cognizant to Support Alnylam's IT Transformation and Accelerate Medicine Delivery

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Alnylam Pharmaceuticals focuses on RNA interference (RNAi) as a method for developing drugs to treat rare genetic diseases.

The company's pipeline includes investigational RNAi therapeutics for genetic diseases.

Alnylam is developing treatments for cardio-metabolic diseases using RNAi technology.

The company is working on RNAi therapeutics for the treatment of infectious diseases.

Alnylam is exploring RNAi-based treatments for diseases affecting the central nervous system and eyes.

Alnylam offers products for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy, and other related conditions.

Canada

India

Asia

United Kingdom

Europe

South Korea

HTML5

Amazon EC2

Google Drive

Adobe Flash

Apache Server

Wordpress

Modernizr

Microsoft Outlook

Bootstrap

Vimeo

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

news impact assignment basic	general	Dec 6, 2024 2:12 AM	ed5ac2b8
public peers	general	Sep 23, 2024 12:52 PM	b8738dc5
news daily refresh	general	Dec 4, 2024 2:16 PM	e5896d18
news processing daily refresh	general	Dec 5, 2024 4:52 AM	8b14cc1b
news impact assignment daily	general
news processing basic	general	Dec 5, 2024 4:49 AM	3d244d61
company summary	general
signals	general	Sep 23, 2024 12:52 PM	1e7d78bc
crunchbase trigger	general	Nov 25, 2024 9:06 AM	a2cd4017
crunchbase profile	general	Nov 25, 2024 11:17 AM	d68df298
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:27 PM	97b365d5
peers	general	Sep 23, 2024 12:52 PM	9f06b88f
news basic	general	Dec 4, 2024 2:13 PM	ccfd8028
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ALNYLAM

Alnylam Pharmaceuticals

Last Close

246.80

22/11 21:00

Market Cap

32.60B

Beta: -

Volume Today

450.15K

Avg: -